Biolab expands international operations with the acquisition of a Canadian company

We are delighted to share the new acquisition of Biolab, the Canadian company Exzell Pharma.
 
Biolab arrived in Canada in 2017 with a research and development unit. In this first phase, the priorities were to understand the legislation and the product registration process, as well as to certify the company's plants in Brazil for export - the plants in Jandira and Bragança Paulista have already achieved certification. It is now moving towards the global market with the purchase of the Canadian laboratory Exzell Pharma, located in Markham, Ontario.
 
The company is being incorporated into Biolab with an average growth of 12% per year and has a portfolio of products for the gastroenterology, dermatology, vitamins and supplements specialties, markets that are booming.
 
The acquisition of Exzell and the incorporation of its line also allows Biolab to evaluate which products can be exported to Brazil and which drugs manufactured here can be taken to Canada.
 
With a population of 38 million people, Canada is one of the world's largest economies and has an important health market (equivalent to Brazil), estimated at around R$ 120 billion a year.
 
This is a big step for Biolab! The purchase of Exzell also represents a great opportunity for growth by establishing an international export platform to other countries from Canada!
 
Long live evolution!